CD276 antibody (AA 29-466)

Catalog No. ABIN5611271

This Mouse Monoclonal antibody specifically detects CD276 in ELISA, FACS, IHC and ICC. It exhibits reactivity toward Human.

Quick Overview for CD276 antibody (AA 29-466) (ABIN5611271)

Target: CD276

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CD276 antibody is un-conjugated

Application: ELISA, Flow Cytometry (FACS), Immunohistochemistry (IHC), Immunocytochemistry (ICC)

Clone: 8C1C2

Product Details anti-CD276 Antibody

Binding Specificity: AA 29-466

Purpose: B7H3 Antibody

Purification: Purified antibody

Immunogen: Purified recombinant fragment of human B7H3 (AA: 29-466) expressed in HEK293 cells.

Isotype: IgG1

Application Details

Application Notes:

ELISA: 1/10000

FCM: 1/200 - 1/400

ICC: 1/100 - 1/500

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Purified antibody in PBS with 0.05 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

Target Details for CD276

Target: CD276

Alternative Name: B7H3

Background: The protein encoded by this gene belongs to the immunoglobulin superfamily, and thought to participate in the regulation of T-cell-mediated immune response. Studies show that while the transcript of this gene is ubiquitously expressed in normal tissues and solid tumors, the protein is preferentially expressed only in tumor tissues. Additionally, it was observed that the 3' UTR of this transcript contains a target site for miR29 microRNA, and there is an inverse correlation between the expression of this protein and miR29 levels, suggesting regulation of expression of this gene product by miR29. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Molecular Weight: 57.2 kDa

UniProt: Q5ZPR3

Pathways: Cancer Immune Checkpoints